QILIAN INTERNATIONAL HOLDING GROUP LIMITED
{{company.company_channel.channel_name}}
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Qilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule 2024-01-12 20:30
Qilian International Holding Group Ltd Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency 2023-07-17 22:30
Qilian Received a Letter from Nasdaq Related to Regain Compliance 2023-04-27 05:00
Qilian Received Notification of Deficiency from Nasdaq Related to not timely Filing of Annual Report Form 20-F 2023-02-24 05:30
Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders 2023-02-17 05:30
Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2022 2022-10-01 04:30
Qilian International Holding Group Limited Reports Fiscal Year 2021 Financial Results 2022-02-12 06:05
Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated Tablets 2022-01-19 20:30
Qilian International Holding Group Limited Releases 2022 Chairman Letter 2022-01-11 20:00
Qilian International Holding Group Limited Announces Inclusion of Gan Di Xin® and Qilian Shan® Oxytetracycline into List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province 2021-11-23 20:00
Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer Prevention 2021-11-15 20:00
Qilian International Holding Group Limited Donates Pharmaceutical Products Gan Di Xin® Worth RMB500,000 and Other Materials to Help Fight Local COVID-19 Epidemic 2021-11-01 20:00
Qilian International Holding Group Limited Completes Phase One of Its Expansion of New Organic Fertilizer Production Facility and Puts It into Production 2021-10-26 20:00
Qilian International Holding Group Limited Received Approval for Oxytetracycline API Export to Egypt 2021-10-13 20:00
1